Inovio Pharmaceuticals, Inc. (INO) Stock Price & How to Invest
Last updated July 2026
Short answer
You can invest in Inovio Pharmaceuticals (INO) by buying shares or fractional shares at any major US broker, through a small-cap biotech ETF that happens to hold it, or as one speculative sleeve of a thematic basket. Inovio is a clinical-stage biotech developing DNA medicines: synthetic DNA plasmids delivered into cells by its proprietary CELLECTRA device to prompt the body to make disease-fighting proteins. Its lead asset is INO-3107 for recurrent respiratory papillomatosis (RRP), a rare disease. The single biggest thing to understand is that this is a pre-revenue, binary clinical-stage biotech: the stock hinges on a small number of regulatory and trial outcomes, has no profits or product sales, and funds itself by issuing new shares, so the risk is far larger than a typical stock.
INO stock price
As of 2026-07-14, Inovio Pharmaceuticals, Inc. (INO) last closed at $1.21, down 11.0% over the past year. Over the past 52 weeks it has traded between $1.05 and $2.87.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Inovio Pharmaceuticals, Inc.'s investor relations page. Walnut is informational, not investment advice.
What does Inovio Pharmaceuticals, Inc. (INO) do?
Inovio Pharmaceuticals is a clinical-stage biotechnology company built around a DNA medicines platform. The idea is to design small circular DNA molecules, called plasmids, that instruct a patient's own cells to produce specific proteins that target disease, and to deliver those plasmids using Inovio's proprietary CELLECTRA device rather than viral vectors or lipid nanoparticles. The company's most advanced program is INO-3107, an immunotherapy for recurrent respiratory papillomatosis (RRP), a rare condition in which HPV-driven benign tumors recur in the airway and often require repeated surgeries. Inovio's broader pipeline has historically centered on HPV-related diseases, including head and neck cancer (INO-3112) and cervical dysplasia (VGX-3100, whose US development was discontinued in 2023 while a partner pursues it in China).
The investment picture in 2026 is dominated by one event: the FDA accepted Inovio's Biologics License Application for INO-3107 and set a target decision date of October 30, 2026, reviewing it under the accelerated approval pathway. As a pre-revenue company, Inovio has no product sales and is not profitable; it funds operations by raising capital, which has meant repeated share issuance and reverse stock splits over the years. Management has guided that cash reserves, boosted by a 2026 offering, extend the runway into early 2027, roughly around the regulatory decision. That tight linkage between a single approval, the cash position, and ongoing dilution is what makes the stock so binary.
What's driving Inovio Pharmaceuticals, Inc. (INO)?
1. INO-3107 FDA decision for RRP
The central catalyst is the FDA review of INO-3107 for recurrent respiratory papillomatosis, with a target decision date around late October 2026 under the accelerated approval pathway. Supporting Phase 1/2 data showed many treated patients needed far fewer airway surgeries. A first approval would give Inovio its first potential commercial product and validate the DNA medicines platform, while a negative or delayed decision would remove the main pillar of the current thesis.
2. DNA medicines platform validation
Inovio's differentiator is its CELLECTRA-delivered DNA plasmid technology, pitched as avoiding the anti-vector immune response seen with viral vectors and the complexity of lipid nanoparticles. Approval or strong clinical readouts in one indication could support the platform's use across other HPV-driven and rare diseases. The platform has, however, been in development for many years without a marketed product, so validation remains unproven until a regulator clears a program.
3. Pipeline breadth beyond RRP
Beyond INO-3107, Inovio has explored HPV-associated head and neck cancer (INO-3112, studied with a checkpoint inhibitor), cervical and anal dysplasia, and other candidates. A partner is advancing a related HPV asset in China. These earlier-stage programs offer optional upside if data progress, but most are years from any filing and carry the usual high failure rates of early clinical development, so they add little near-term certainty.
4. Cash runway and financing
As a company with no product revenue, Inovio depends on its cash balance and capital markets to fund trials and a potential launch. Management has indicated its cash, aided by a 2026 equity raise, funds operations into roughly early 2027, near the regulatory decision. That leaves little margin: additional raises, partnerships, or milestone events may be needed, and each equity issuance dilutes existing shareholders, a recurring feature of the stock's history.
What are the risks to Inovio Pharmaceuticals, Inc. (INO)?
The dominant risk is binary clinical and regulatory outcome: the stock is tightly bound to the INO-3107 FDA decision, and rejection, a delay, or a request for more data could sharply reduce the company's value. As a pre-revenue biotech, Inovio has no product sales, is not profitable, and has a history of operating losses, so it relies on issuing new stock to survive; this dilution can erode per-share value even when clinical news is neutral, and the company has done multiple reverse stock splits over time. Cash runway is finite and roughly aligned to the regulatory decision, leaving little cushion if timelines slip. Even with an approval, commercial success in a rare disease is uncertain, requiring reimbursement, adoption, and manufacturing execution. Broader risks include competition, dependence on the unproven CELLECTRA platform, and the high overall failure rate of clinical-stage drug development.
How is Inovio Pharmaceuticals, Inc. (INO) valued? (approximate, Jul 2026)
A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Inovio Pharmaceuticals, Inc.'s investor relations page or your broker.
- Revenue: Effectively none; pre-revenue with no approved product on the market
- Profitability status: Not profitable; sustained operating losses funded by capital raises
- Cash runway: Management guided into roughly early 2027, near the target FDA decision
- Lead program stage: INO-3107 (RRP) BLA under FDA review; target decision date around late Oct 2026
- Market cap: Small-cap and highly volatile; moves sharply on trial and regulatory news
- Analyst view: Coverage is limited and speculative, framed around the binary approval catalyst
Standard valuation multiples do not apply here: Inovio is pre-revenue and unprofitable, so metrics like P/E are meaningless and the equity is effectively an option on a small number of clinical and regulatory outcomes. Value is driven by the probability and timing of an INO-3107 approval, the cash runway, and dilution, not by earnings. Verify the latest cash position, share count, and program status before acting, as they can change quickly.
Who competes with Inovio Pharmaceuticals, Inc. (INO)?
RRP and HPV-disease therapeutic developers
Inovio's lead indication, recurrent respiratory papillomatosis, is targeted by other approaches including systemic immunotherapies, therapeutic HPV vaccines, and antiviral or checkpoint-based strategies from various biotechs and academic programs. In HPV-associated cancers and dysplasia more broadly, Inovio competes with companies pursuing therapeutic vaccines and immunotherapies aimed at HPV-driven disease.
DNA, mRNA, and nucleic-acid platform biotechs
Inovio's DNA plasmid and CELLECTRA delivery approach competes conceptually with mRNA and other nucleic-acid platforms from firms such as Moderna and BioNTech, as well as gene- and cell-therapy developers. These better-capitalized platforms pursue vaccines and immunotherapies with different delivery technologies, and their progress shapes investor perception of DNA-based medicine.
Large vaccine and immunotherapy players
Established pharma and biotech companies including Merck (a leader in HPV prophylactic vaccines with Gardasil), Pfizer, and major immuno-oncology firms have vastly greater resources, commercial reach, and pipelines. While not always direct competitors in RRP specifically, they dominate the broader vaccine and immunotherapy landscape Inovio operates within.
How to invest in Inovio Pharmaceuticals, Inc. (INO)
There are three common ways to get INO exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so INO sits alongside other stocks that express the same thesis.
Walnut takes the basket route. Describe a thesis where INO fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
The bottom line on Inovio Pharmaceuticals, Inc. (INO)
Inovio is a pre-revenue, speculative biotech whose value rides on a handful of binary catalysts, above all the FDA decision on INO-3107 for RRP. A favorable outcome could re-rate the stock; a setback or continued dilution could severely impair it. This is a high-risk position, not a stable holding.
Build a basket around INO with Walnut
Use Inovio Pharmaceuticals, Inc. as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is INO a good stock to buy right now?
+
That depends on your goals, time horizon, and risk tolerance, and this is not investment advice. INO is a speculative, pre-revenue clinical-stage biotech whose value hinges on binary outcomes, above all the FDA decision on INO-3107 for RRP. A favorable decision could re-rate the stock, while a setback, delay, or further dilution could impair it heavily. It carries far more risk than a typical stock, so weigh it carefully against the rest of your portfolio.
What does Inovio Pharmaceuticals actually do?
+
Inovio is a clinical-stage biotech developing DNA medicines. It designs synthetic DNA plasmids intended to instruct a patient's own cells to make disease-fighting proteins, and delivers them using its proprietary CELLECTRA device instead of viral vectors. Its lead program, INO-3107, targets recurrent respiratory papillomatosis, a rare HPV-driven airway disease. It has no approved product on the market yet.
Why is INO stock so volatile?
+
Inovio is a pre-revenue biotech, so its value rests on a small number of clinical and regulatory events rather than on earnings or product sales. News about a trial result, an FDA decision, or a capital raise can move the stock sharply in either direction. This binary, catalyst-driven nature, combined with a small market cap, makes for large and sudden price swings.
Does Inovio pay a dividend?
+
No. Inovio is an unprofitable, pre-revenue biotech that reinvests all of its capital into research, trials, and operations, and it raises money by issuing new shares. Companies at this stage do not pay dividends, so there is no income component to owning the stock. Any return would have to come from share-price appreciation, which is highly uncertain.
What are Inovio's lead programs?
+
The most advanced program is INO-3107 for recurrent respiratory papillomatosis (RRP), whose Biologics License Application is under FDA review with a target decision date around late October 2026. Earlier-stage work has included HPV-associated head and neck cancer (INO-3112) and cervical dysplasia (VGX-3100, whose US development was discontinued while a partner pursues it in China). The pipeline is concentrated in HPV-driven diseases.
How long is Inovio's cash runway?
+
Management has guided that its cash, cash equivalents, and short-term investments, helped by a 2026 equity offering, fund operations into roughly early 2027, which is near the target FDA decision date for INO-3107. That leaves limited cushion, so additional financing, a partnership, or a milestone may be needed depending on outcomes. Always verify the latest reported cash position and burn rate.
Who does Inovio compete with?
+
In its lead indication, RRP, Inovio faces other immunotherapy and therapeutic-vaccine approaches. On the platform side, it competes with mRNA and nucleic-acid developers such as Moderna and BioNTech and other gene-therapy firms. More broadly, large vaccine and immunotherapy players like Merck and Pfizer dominate the HPV and immunotherapy landscape with far greater resources.
Can I get exposure to Inovio through an ETF?
+
INO can appear in some small-cap, biotech, or broad healthcare ETFs, but as a small and speculative name its weighting tends to be very small, so a fund gives you only a diluted sliver of exposure. ETF holdings also change over time. Always check a fund's current holdings and weights before assuming meaningful exposure to Inovio specifically.
What are the main risks of investing in INO?
+
The biggest risk is binary regulatory and clinical outcome: the stock is tied closely to the INO-3107 FDA decision, and a rejection or delay could sharply cut its value. It is pre-revenue and unprofitable, relies on dilutive share issuance to survive, and has a finite cash runway. Even an approval would require commercial success in a rare disease. The unproven platform, competition, and high biotech failure rates add further risk.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Inovio Pharmaceuticals, Inc.'s investor relations page or your broker before making investment decisions.